U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION

+ + + + +

NATIONAL INSTITUTE FOR OCCUPATIONAL
SAFETY AND HEALTH
ADVISORY BOARD ON RADIATION AND
WORKER HEALTH

SUBCOMMITTEE FOR DOSE RECONSTRUCTION REVIEW

+ + + + +

+ + + + +

WEDNESDAY, MAY 6, 2009

+ + + + +

The meeting convened at 11:00 a.m. via teleconference, Mark Griffon, Chairman, presiding.

#### PRESENT:

MARK GRIFFON, Chairman BRADLEY P. CLAWSON, Member MICHAEL H. GIBSON, Member WANDA I. MUNN, Member

THEODORE M. KATZ, Acting Designated Federal Official

### IDENTIFIED PARTICIPANTS:

NANCY ADAMS, NIOSH Contractor EMILY GUNN, GAO EMILY HOWELL, HHS OGC ROY LLOYD, HHS JOHN MAURO, SC&A ROBERT MCGOLERICK, HHS MUTTY SHARFI, ORAU SCOTT SIEBERT, ORAU

# TABLE OF CONTENTS

Roll Call								4
Discussion	of	Draft	Fir	rst	100	Cases	Report	9
Discussion	of	Revisi	ion	of	Case	e Seled	ction	37
Criteria								

1	P-R-O-C-E-E-D-I-N-G-S
2	11:00 a.m.
3	MR. KATZ: So, let's start with
4	roll call, so, Mark?
5	CHAIRMAN GRIFFON: Mark Griffon,
6	Chair of the Subcommittee on Dose
7	Reconstruction.
8	MR. KATZ: Other Board members?
9	MEMBER CLAWSON: Brad Clawson,
10	Advisory Board member and on the workgroup of
11	the Subcommittee.
12	MEMBER GIBSON: Mike Gibson,
13	Advisory Board member and a Subcommittee
14	member.
15	MR. KATZ: Okay, how about I
16	know Bob Presley is on the road.
17	CHAIRMAN GRIFFON: Wanda and John
18	Poston.
19	MR. KATZ: Yes, and John may be
20	traveling, because I know he responded to Jim
21	Melius for the workgroup meeting on Friday
22	and said he would be overseas at that point.

1	So, I'm not sure he's here today. I'm not
2	sure whether he's here or not today, but I
3	didn't get a response. Let's give Wanda a
4	couple minutes before we go on with the roll
5	call.
6	Zaida, are you on?
7	MS. BURGOS: Yes.
8	MR. KATZ: Can you give Wanda a
9	ring, just in case? I know it's earlier her
10	time, just to be certain.
11	MS. BURGOS: I will.
12	MR. KATZ: Thanks.
13	CHAIRMAN GRIFFON: Mike and Brad,
14	you've got the revised copy of the report,
15	right?
16	MEMBER CLAWSON: Yes, I do.
17	MEMBER GIBSON: I've got it.
18	CHAIRMAN GRIFFON: Okay, good.
19	MS. BURGOS: Ted?
20	MR. KATZ: Yes.
21	MS. BURGOS: She'll be on the
22	phone in a few minutes.

1	MR. KATZ: Okay, thank you.
2	MEMBER MUNN: Hello.
3	CHAIRMAN GRIFFON: Hi, Wanda?
4	MEMBER MUNN: Yes.
5	MR. KATZ: Welcome, Wanda.
6	MEMBER MUNN: Hi, sorry I wasn't
7	on earlier. A long-time friend and
8	colleague, one of our former Commissioners,
9	died the day before yesterday, and I only
10	learned about it yesterday. The burial was
11	this morning, and I was a little distracted.
12	MR. KATZ: I'm sorry to hear that.
13	MEMBER MUNN: Yes, so am I. I was
14	just thinking about getting to the funeral
15	home instead of where I ought to be. Sorry
16	about that.
17	MR. KATZ: Okay, so we're done
18	with roll call up through you, Wanda.
19	Let me just check again before we
20	go beyond Board Members, Dr. Poston or Bob
21	Presley, are either of you on the line?
22	Okay, then carrying on, how about

1	NIOSH ORAU team, are there any NIOSH ORAU
2	team members on the line? Stu told me he
3	wouldn't be making the meeting today.
4	MR. SIEBERT: Scott Siebert with
5	the ORAU team.
6	MR. KATZ: Welcome, Scott.
7	MR. SIEBERT: Thank you.
8	MR. SHARFI: Mutty Sharfi, ORAU
9	team.
10	MR. KATZ: Can you repeat that, it
11	was hard to understand you.
12	MR. SHARFI: Mutty Sharfi.
13	MR. KATZ: Any others? Okay.
14	And then, how about the SC&A team?
15	DR. MAURO: John Mauro here.
16	MR. KATZ: Any others from SC&A?
17	Okay.
18	Then, how about other HHS
19	employees or contractors?
20	MS. HOWELL: Emily Howell, HHS.
21	MR. McGOLERICK: Robert
22	McGolerick, HHS.

1	MR. LLOYD: Roy Lloyd, HHS.
2	MS. ADAMS: Nancy Adams, NIOSH
3	contractor.
4	MR. KATZ: Welcome all of you.
5	And, any other then any other
6	Federal employees, DOL, DOE? I know I heard
7	somebody from GAO, Emily Gunn, was on the
8	line earlier.
9	MS. GUNN: Yes, I'm still here.
10	MR. KATZ: welcome, Emily.
11	MS. GUNN: Thank you.
12	MR. KATZ: Okay. Anyone from the
13	Department of Labor and Department of Energy?
14	Okay.
15	And then, any members of the
16	public or staff from congressional offices
17	who want to self identify?
18	Okay then, Mark, it's all yours.
19	CHAIRMAN GRIFFON: Okay. Well, I
20	guess we have a short agenda, and, you know,
21	it could take a little time or a lot of time,

1	The main focus, I think, is the
2	leftover draft hundred case, first hundred
3	cases report, and I sent a revised a
4	revision out based on the comments from the
5	last Subcommittee meeting.
6	And, Wanda, I checked with Mike
7	and Brad, you got a copy, correct, Wanda?
8	MEMBER MUNN: Hold on, I'm just
9	double checking to see.
10	CHAIRMAN GRIFFON: Okay.
11	MEMBER MUNN: I think I recall
12	reading that. Time has been a bit compressed
13	here in the last week.
14	CHAIRMAN GRIFFON: Anyway, I'll
15	just talk while Wanda is looking for that.
16	MEMBER MUNN: Yes, what day did
17	you send that?
18	CHAIRMAN GRIFFON: Oh, it was a
19	just few days either yesterday or the day
20	before.
21	MEMBER MUNN: Yes, I thought it
22	was

1	CHAIRMAN GRIFFON: Yesterday
2	morning, I think.
3	MEMBER MUNN: I'm double
4	checking.
5	CHAIRMAN GRIFFON: I really
6	intended to get it out earlier, but that was
7	pretty early for our standards.
8	And then, the other item on the
9	agenda, you know, if we have I mean, I
10	think this is the more pressing one, but the
11	other item was the revisiting the case
12	selection criteria, we had committed to that
13	that was a request of the overall Board,
14	that we reexamine our original case selection
15	criteria and see if we had to modify it at
16	all.
17	And, I found, I forwarded also an
18	old flow diagram, which gives some
19	information. I also have some other
20	information from Kathy Behling has
21	forwarded me a draft database similar to the

Procedures Work Group, or Procedures

Subcommittee, that has some of the case statistics up through the first 120 cases. So, that also can be kind of helpful in this discussion, although it's not available for everybody, it's kind of a draft that Kathy sent to me to start using on this committee. Hopefully, by the next meeting maybe we'll have something like that set up.

But anyway, those are the two items, and I guess I can describe what I did on the revision. You should clearly see the changes, they are either in red or some other color, but they are definitely highlighted in the drafts that I sent around.

And, the idea was to sort of describe -- well, it was just a question of, I never really got to the bottom line, and everyone at the last meeting thought it would be useful to describe like the three -- I think it can be broken down a little further, I think Stu, in one of his graphs, broke it out a little more precisely, but there's

#### **NEAL R. GROSS**

three general categories of dose reconstructions that we looked at, and they were best estimate, the over-estimated cases, and the under-estimated cases.

And, I tried to describe, you know, what percentages we found, what percentages there are overall in the case population as of, you know, 20,000 cases, that was the graphic that Stu sent around to me, maybe to everyone, I'm not sure.

And then, to go into each one of those types of cases, just quickly, you know, for the best estimate, what were our overall impressions for the over-estimated cases, what were our overall impressions, and for the under-estimated cases what were our overall impressions, and then the rest of the report remains. We've discussed the rest of the report, it remains unchanged, basically.

So, those were the -- that was the front end that I tried to add. It's getting a little longer, but it also, I think, just

#### **NEAL R. GROSS**

1	gives a little better sort of more executive,
2	you know, more executive-type summary that we
3	were looking for. At least that was my
4	intent.
5	I guess that's my overall
6	description. I certainly think there might
7	be some wording, you know, that we can work
8	on, but I would open it up for your overall
9	impressions, the other committee members.
10	Well, that's a good impression.
11	MEMBER MUNN: I'm scanning through
12	this right now.
13	CHAIRMAN GRIFFON: Okay. All
14	right.
15	MEMBER MUNN: I'll have to be
16	truthful, the only opportunity that I had to
17	see my e-mail yesterday was a very brief
18	scanning
19	CHAIRMAN GRIFFON: Oh, okay.
20	MEMBER MUNN: last night of
21	what was on it.
22	CHAIRMAN GRIFFON: Okay

1 MEMBER MUNN: And, I am just now 2 scanning it. CHAIRMAN GRIFFON: That's why I 3 was talking so long, to give people time to 4 read through it again. 5 MEMBER MUNN: Well, yes, my 6 apologies for that. 7 CHAIRMAN GRIFFON: I can see some 8 things already, like the last sentence in the 9 10 second paragraph, I think I sort of need to describe a little better, because I'm 11 comparing the percentages for the first 12 13 20,000 cases to the percentages for those that we reviewed. And, I think that last 14 15 sentence might be better if it said of the 16 cases discussed in this report 7 percent were best estimate, 76, you know, because I think 17 it's a little confusing to the reader. 18 19 MEMBER MUNN: Yes, in this report it's much better. 20 CHAIRMAN GRIFFON: Yes, there's 21 little things like that. 22

1	MEMBER MUNN: So, there's that
2	revision.
3	DR. MAURO: Mark, this is John. I
4	read through it. I did catch a couple of
5	typos.
6	CHAIRMAN GRIFFON: Sure, I'll take
7	those friendly amendments, too.
8	DR. MAURO: These are all
9	friendly. By the way, I think the Executive
10	Summary is excellent. I think that, you
11	know, when I read it I said, yes, this really
12	tells the story nicely on the right level.
13	But, in any event, you know,
14	whenever you want I have two or three places
15	where I have some suggestions, mainly typos.
16	CHAIRMAN GRIFFON: People can even
17	e-mail those.
18	DR. MAURO: Okay.
19	CHAIRMAN GRIFFON: I mean, as long
20	as it's not I mean, Ted, that's fine, if
21	we can vote on the sense of the report, I'm
22	certainly willing for wordsmithing at a later

1	date before we bring to the Board. I think
2	that's acceptable. We can it would be
3	nice if we could, by the end of this meeting,
4	have a sense of the committee, the
5	Subcommittee, whether we can bring this as a
6	motion from the Subcommittee before the Board
7	next week, and then we can, I think, I can
8	revise with edits and those kind of things
9	without altering that motion.
10	MR. KATZ: Yes, Mark, I completely
11	agree. I don't think you need to do close
12	copy editing in this meeting. That's fine.
13	CHAIRMAN GRIFFON: I think that
14	would be cumbersome, especially, over the
15	phone like this.
16	MEMBER MUNN: I guess I'd make one
17	suggestion. That first paragraph on the
18	second page.
19	CHAIRMAN GRIFFON: First paragraph
20	on the second page.
21	MEMBER MUNN: Where we are talking
22	about the dose reconstructions, in the next

1	to the last
2	CHAIRMAN GRIFFON: Tell me what
3	the line starts with; I'm not sure where you
4	are.
5	MR. KATZ: Wanda, hang on one
6	second, I didn't I failed to note, because
7	I thought all of were for this meeting the
8	main thing is not actually speaking, please
9	mute your phone so that we don't have
LO	interference with the people who are trying
11	to speak. And, if you don't have a mute
12	button, you can you use *6. Thanks.
L3	Hello? We are hearing someone
L4	with a sidebar discussion. Please mute your
L5	phone so that it doesn't interfere with the
L6	call.
L7	MEMBER MUNN: We still have a
18	woman in the background.
L9	MR. KATZ: Zaida, can you cut the
20	line that's interfering?
21	MS. BURGOS: I will.
22	MR. KATZ: Thank you.

1	CHAIRMAN GRIFFON: Let's just wait
2	for this to subside here. You'd think with
3	these small ones we'd be all right, right?
4	MEMBER MUNN: Yes, you would
5	think.
6	MR. KATZ: Not everybody is a
7	regular here, so
8	MEMBER MUNN: I think I can talk
9	over that.
10	CHAIRMAN GRIFFON: All right, I
11	think I can hear you.
12	MR. KATZ: But, it's very hard for
13	the court reporter, who has to follow this.
14	MEMBER MUNN: Oh, yes, that's
15	right, it is.
16	Perhaps, we need to
17	MR. KATZ: It doesn't sound like
18	the line is cut, but maybe they've stopped
19	talking.
20	MS. BURGOS: He's working on it
21	now.
22	MR. KATZ: Okay. Are the rest of

1	you still there?
2	CHAIRMAN GRIFFON: We got it, yes.
3	MR. KATZ: Yes, okay.
4	CHAIRMAN GRIFFON: Okay.
5	MEMBER MUNN: A fairly simple
6	thing, but the next to the last sentence on
7	that first paragraph on the second page says,
8	"While the dose reconstruction may be
9	appropriate, this has created real confusion
10	about the claimant population." And, I
11	agree, it has created real confusion, but I
12	don't feel among the claimant population as a
13	whole, I think it's the people who have
14	actually experienced that.
15	CHAIRMAN GRIFFON: Right, that's
16	true.
17	MEMBER MUNN: And, among the
18	claimants who have experienced.
19	CHAIRMAN GRIFFON: Yes, among the
20	claimants who have experienced, yes, okay.
21	MEMBER MUNN: Yes.
22	CHAIRMAN GRIFFON: Okay, that's

fine, yes. Yes, I agree. Okay.

And then, as you are reading on,
Wanda, the last section there is the 17 cases
with the under-estimating approach, and they
were all over 50 percent, so they were, you
know --

MEMBER MUNN: Right.

CHAIRMAN GRIFFON: -- I think we pretty much agreed that they were appropriately done.

MEMBER MUNN: Yes.

CHAIRMAN GRIFFON: I think there's one thing in the -- there's one edit that I'm going to make, the over-estimated approach for, it says six cases that were compensated.

Kathy Behling sent me a late e-mail last night that, actually, concurred with my number, which was eight, and originally she had told me six. But, John, you can double check that maybe with Kathy, but I'm pretty sure that's correct.

DR. MAURO: Yes, right now it says

#### **NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701 several, six.

CHAIRMAN GRIFFON: Oh, several six, yes, I knew we had several, and then we had a number, yes, it's, actually, for eight cases. So, I'll replace the several six with eight cases in that section.

The only other thing I was
thinking if you go back to the first page,
after the second paragraph I was considering,
because, Ted, really, those lines were added
after you e-mailed me and reminded me that we
had asked for that one sort of comparison,
and I think it needs to be put in some
context. And, as I was looking through the
case selection criteria I think I might have
the context.

But, you know, it looks as though, based on that, I would read this to say 20,000 cases, 8 percent, best estimate, 63 are over-estimates, and 29 under-estimates, and then of the first 100 cases, or of those discussed in this report, we kind of have the

same percentages almost. It's pretty -- you
know, fairly close.

I was going to add on a sentence, though, to remind the reader, or to tell the reader, because I don't know if we ever mentioned this, but in our original approach to the dose review, as you'll see in the flow chart for the selection criteria, we really intended on -- and I was going to say it should be noted that the Board's intent was to review a greater percentage of the bestestimate cases, and as you'll see in our criteria we, actually, said we were looking for like 40 percent of our cases to be from the 45-50 percent range, and I think the intent there was that that's where NIOSH had to sharpen their pencils, so to speak, and, you know, that's where issues regarding -that could affect compensation are more likely to be -- you know, show up. that's where we wanted to focus our review.

So, even though the percentages

#### **NEAL R. GROSS**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	were close in our original audit, we want to
2	put more emphasis on the best-estimate cases.
3	I don't know if that needs to be in there at
4	all, but just a thought.
5	MEMBER MUNN: My question was
6	going to be so you are suggesting that you
7	add another sentence of explanation?
8	CHAIRMAN GRIFFON: Yes, just
9	MEMBER MUNN: Actually, this looks
10	fine to me.
11	CHAIRMAN GRIFFON: all right,
12	maybe we'll just leave it like that. It
13	reads fine, I guess, yes.
14	MEMBER MUNN: Yes.
15	CHAIRMAN GRIFFON: All right, I'll
16	just leave it like that. I guess I don't
17	need to put any, you know, judgment on it.
18	MR. KATZ: Yes, Mark, I just
19	you know, it doesn't need to be there. If
20	you wanted to add a paragraph about going
21	forward, I think that would be perfectly
22	appropriate to add if you want it. I don't

1	think it's essential.
2	CHAIRMAN GRIFFON: Yes.
3	MR. KATZ: But, if it's something
4	that, you, is frequently done in these sort
5	of reports, it's completely up to you.
6	CHAIRMAN GRIFFON: Okay.
7	MEMBER MUNN: And, I guess my
8	instinct would be not to include anything
9	about what comes next week, or next month, or
10	next year. These reports are, in my view,
11	complex enough as they are.
12	CHAIRMAN GRIFFON: Right.
13	MEMBER MUNN: And, we have not
14	at least I have not assimilated any feeling
15	that we need to change the concept of these
16	occasional reports.
17	CHAIRMAN GRIFFON: Okay, I'll
18	leave that out. It was just a thought as I
19	was reading through.
20	DR. MAURO: Mark, I just had a
21	thought. Do you think it would be worth
22	mentioning that at the time of preparing this

1	report on the first 100, we currently have
2	the Board audited, or in the process of
3	auditing 240? As of this date, the 240 have
4	been reviewed by SC&A, and, of course, all of
5	which are at various stages of issues
6	resolution. I don't know if that's the kind
7	of thing that would get like up to date.
8	CHAIRMAN GRIFFON: I'm not sure if
9	that's just
10	DR. MAURO: Just a thought.
11	CHAIRMAN GRIFFON: yes. I just
12	I'm not sure we need to have that in
13	there, what other people think. I just think
14	that might add confusion, like, well why are
15	you so far behind on the ones that have
16	already been done.
17	MEMBER CLAWSON: Mark, this is
18	Brad. I've got to agree with you. I think I
19	guess I could be considered as layman as
20	anybody, but it would just add a little more
21	confusion to it.

## **NEAL R. GROSS**

CHAIRMAN GRIFFON:

22

I know, I know.

1 John, I just feel -- you know, because I 2 feel like that would be -- I might need to explain that a little further, and I don't 3 want to make it any --4 DR. MAURO: No problem. 5 CHAIRMAN GRIFFON: -- more lengthy 6 than it is. 7 DR. MAURO: Like I said, we were 8 talking about -- you are absolutely right. 9 10 CHAIRMAN GRIFFON: I already thought, as I was adding this stuff, that it 11 was getting a little lengthy, but I did want 12 13 to take enough sentences to explain, because we throw around these terms, best estimate, 14 15 over-estimate, under-estimate, you know, so I 16 thought it was worth a sentence or two of explanation of what we meant by that. 17 I hope that's okay. If there's 18 19 some wordsmithing there, too, that NIOSH has comments on for defining those parameters, I 20

#### **NEAL R. GROSS**

slightly erroneous, you know, regarding the

would take those, if I am saying something is

21

efficiency process or whatever.

MR. KATZ: Mark, actually, my

perspective, I, actually, think you've

handled this really well with all the new

material, and I think it's just -- as Dr.

Mauro said, I think it's a really good sort

of overview for the Secretary. I think it

really did sort of hit the nail on the head,

and I think that's great.

CHAIRMAN GRIFFON: Okay

MR. KATZ: The one thing I would just suggest, in terms of titling this, it's not -- this is really sort of what I would just call an introduction to the Executive Summary, rather than just Executive Summary, because part of this is context that you are giving up front, which I think it absolutely right, isn't repeated in the body of the report.

CHAIRMAN GRIFFON: Right. So, an introduction.

MR. KATZ: Normally, an Executive

#### **NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1	Summary really does just summarize what's in
2	the body of the report. This, actually,
3	gives context that is needed, but it's not in
4	the body. So, you may then either repeat it
5	in the body of the report or just say, you
6	know, introduction and Executive Summary.
7	CHAIRMAN GRIFFON: Well, I surely
8	don't want to repeat it anymore.
9	MEMBER MUNN: Please, let's don't
10	repeat.
11	MR. KATZ: That's what I would
12	suggest, that's all.
13	CHAIRMAN GRIFFON: So, just
14	introduction and Executive Summary, or just
15	introduction?
16	MR. KATZ: I would just or you
17	can even just call this, you know, an
18	introduction, that's fine.
19	CHAIRMAN GRIFFON: Yes, maybe just
20	introduction.
21	MR. KATZ: Fine.
22	MEMBER MUNN: Background or

1 whatever. 2 CHAIRMAN GRIFFON: Yes. And, the title, of course, yes, some of those things 3 4 on the top, we can re-title them. I'm not too worried about that, you know, however 5 Paul wants to format, you know, consistent 6 7 with the other reports that we submitted, I think that's how, you know, Paul can work 8 that out. 9 10 MEMBER MUNN: Yes, I have to agree, the new verbiage is good. 11 I, as always, resist adding any 12 13 words to anything. CHAIRMAN GRIFFON: I know. 14 MEMBER MUNN: But --15 CHAIRMAN GRIFFON: When I saw the 16 pages going up, Wanda, so I was thinking of 17 you, you don't want it too long. 18 19 MEMBER MUNN: -- and then in II, the last item is titled, "Finding Resolution 20

Process." And, even though when I looked at

that I thought, we're finding the resolution

21

1	process, we already know the resolution
2	process.
3	Could we, perhaps, call that
4	instead resolution process of findings?
5	Would that be a little clearer than
6	CHAIRMAN GRIFFON: Or, just
7	resolution process maybe, resolution process
8	of findings?
9	MEMBER MUNN: Yes.
10	CHAIRMAN GRIFFON: Or just
11	resolution process.
12	MEMBER MUNN: Well, either, but
13	resolution process of findings, we said
14	findings in each of the headings.
15	CHAIRMAN GRIFFON: Okay,
16	resolution process of findings, that's fine.
17	MEMBER MUNN: Yes.
18	CHAIRMAN GRIFFON: Okay. All
19	right.
20	MEMBER MUNN: I'm not even reading
21	any other words except
22	CHAIRMAN GRIFFON: I have not

touched the rest of it, you can see the red ones, yes, I haven't touched the other part of the report, and I think, basically, we are all happy with that.

And, the attachment, I'm going to go with Kathy's latest update on the attachments that we looked at before, which give the sort of summary, you know, statistics on the breakout of the cases for the first 100, and I can forward that to people, you know, just for your information.

I think you all have it, but maybe when I do these edits, you know, before the Board meeting I'll do one final edit and send it all around.

MEMBER MUNN: Yes, those graphs were particularly nice I think.

I'm a little puzzled about the other file that came along.

CHAIRMAN GRIFFON: Well, that's for the next discussion, which is our case selection criteria.

#### **NEAL R. GROSS**

1	MEMBER MUNN: Okay.
2	CHAIRMAN GRIFFON: That doesn't go
3	with this report at all.
4	MEMBER MUNN: It's a good thing.
5	CHAIRMAN GRIFFON: Right, no, that
6	was
7	MEMBER MUNN: I'm not getting that
8	part.
9	CHAIRMAN GRIFFON: this is
10	probably, I found this is there a date on
11	it? Well, I don't know, it must be an auto
12	date thing.
13	MEMBER MUNN: Yes, it probably is.
14	CHAIRMAN GRIFFON: Because it says
15	2009. This I probably did in 2003, I think,
16	anyway, I found this in an old file with, you
17	know, some of our first discussions of
18	selection criteria.
19	MEMBER MUNN: When we were first
20	getting started, yes.
21	CHAIRMAN GRIFFON: But, let's

1	everybody is in agreement, other than, you
2	know, sort of grammatical things.
3	DR. MAURO: Mark, this is John.
4	There is one substantive
5	suggestion I have in Item No. 6 in the main
6	body of the report, you know, items, issues
7	regarding scientific judgments and
8	assumptions.
9	CHAIRMAN GRIFFON: Yes.
10	DR. MAURO: At the end of that you
11	identify two examples, where there are more
12	problems.
13	CHAIRMAN GRIFFON: Right.
14	DR. MAURO: There's a third, that
15	we have discussed recently.
16	CHAIRMAN GRIFFON: Okay.
17	DR. MAURO: Whether it applies to
18	this 100, I'm not sure, but it has to do
19	and this is conceptual it has to do with
20	when we review a lot of these exposure
21	matrices which are applied to the AWEs
22	CHAIRMAN GRIFFON: Right.

1	DR. MAURO: we are finding that
2	they are using a one size fits all, and very
3	often this information in the CATI report and
4	in the main body of the dose reconstruction
5	pertaining to the job category that this
6	particular worker had. That is not factored
7	in. In other words, the automatic would just
8	apply.
9	CHAIRMAN GRIFFON: Yes, I know
10	what you are saying.
11	DR. MAURO: And, I thought that
12	was a third item that would fit in nicely
13	here, if you feel it's worth mentioning.
14	CHAIRMAN GRIFFON: Yes. I know
15	we'll capture I know we've been discussing
16	that lately, I just I hesitate to edit
17	this at all because
18	DR. MAURO: I understand.
19	CHAIRMAN GRIFFON: we've
20	discussed that part, and it may have come up
21	more in recent cases than in this first 100.
22	DR. MAURO: That's true, it really

1	came up, I would say, in the last couple of
2	rounds of discussion.
3	CHAIRMAN GRIFFON: Yes, I mean, I
4	think everyone around you know, all
5	NIOSH is aware of it, we are all aware of it
6	I just hate to confuse this report on the
7	first 100.
8	DR. MAURO: No problem.
9	MEMBER MUNN: And, that seems to
10	be so much more of a CATI item than it is
11	DR. MAURO: It, actually, is more
12	of a CATI item.
13	CHAIRMAN GRIFFON: Yes, its' kind
14	of an overlapping with the CATI, yes.
15	MEMBER MUNN: Yes.
16	CHAIRMAN GRIFFON: So, I would
17	rather not add that in yet, John. I mean,
18	certainly, you are right, we have been
19	discussing that quite a bit, so
20	DR. MAURO: Okay.
21	CHAIRMAN GRIFFON: We'll capture
22	it at some point.

1	MEMBER MUNN: I think some sense
2	of that is captured in No. 1.
3	CHAIRMAN GRIFFON: Yes.
4	Okay, if there's no further, other
5	than, you know, grammatical and things like
6	that, is everybody comfortable bringing this
7	as a recommended report from the
8	Subcommittee?
9	MEMBER MUNN: I certainly am.
10	CHAIRMAN GRIFFON: I don't think
11	we have to vote on it, but Brad or Mike?
12	MEMBER CLAWSON: This is Brad. I
13	feel comfortable with it.
14	CHAIRMAN GRIFFON: All right.
15	MEMBER GIBSON: I agree. Mike.
16	CHAIRMAN GRIFFON: All right,
17	great. I think we got it.
18	MEMBER MUNN: Good.
19	CHAIRMAN GRIFFON: I'm glad,
20	because this is revision six for me.
21	MEMBER MUNN: Well, I know, and
22	it's a long, difficult thing, but

CHAIRMAN GRIFFON: But, I do

appreciate, I mean, I think everybody was

right to force me to sort of work a little

harder on that front end, because it does -
we needed a little context for the report.

so, I think it's a reasonable product now.

MEMBER MUNN: Well, and I do
believe that this is not going to be any
different than most of the material that
crosses the desks of the upper echelon, the
first page or two is going to tell the story
for them, or not at all.

CHAIRMAN GRIFFON: Sure. Sure.

Okay, let's go on to our second topic, and maybe we can, actually, end the conference call early. That would be something new for us, huh?

Let's see, this is -- we had been asked by the overall Board to sort of reexamine the case selection process, and this, as Wanda pointed -- I mean, this is a sort of primitive flow sheet, it gives us an

#### **NEAL R. GROSS**

idea. I sent it along because it was the best -- actually, one of the only things I could find that sort of laid out some of the original parameters we were looking at, as far as when we selected the cases.

But, you know, these categories on the left, probable causation, facility, decade, duration, obviously, are ones we've been considering, and as I said, it was interesting to look back and say, okay, from zero to 45 we were thinking of, you know, our goal was 40 percent of our overall cases that we reviewed would fall into that category, and 40 percent would fall into the middle 45 to 50 percent category. And then, 20 percent, you know, compensable cases above 50 percent.

So, I, actually, have, if I can find it, have the draft database, as I said, from Kathy, and -- well, actually, she sent some more stuff. So, maybe I have it hot off the press. I'm sorry, bear with me here, she

#### **NEAL R. GROSS**

1	just sent this a little while ago, this is
2	the 258 cases overview for POC. So, she gave
3	me a breakdown on all the POCs for the first
4	258.
5	Anyway, I guess there were two
6	questions. One is the criteria, and then I
7	think the other was the overall sample,
8	right? I mean, I think we were targeting 2-
9	1/2 percent of all cases.
10	MEMBER MUNN: Of the total.
11	CHAIRMAN GRIFFON: Of the total,
12	you know, sort of
13	MEMBER MUNN: Yes, that was the
14	original intent.
15	CHAIRMAN GRIFFON: Right. And, I
16	don't know where does anyone on the phone
17	have a number? I mean, this 20,000 might be
18	out of date.
19	DR. MAURO: Yes, I think we are
20	really operating at around 1 percent, in the
21	grand scheme of things, as opposed to 2-1/2

percent.

1	CHAIRMAN GRIFFON: Well,
2	currently, but I mean, yes, yes.
3	DR. MAURO: But, of the first 100
4	where we were at that time, I think you might
5	be on target.
6	CHAIRMAN GRIFFON: Yes.
7	MEMBER MUNN: Right.
8	CHAIRMAN GRIFFON: Well, how many
9	cases, I mean, can anyone from NIOSH give me
10	a number on that. Scott? Scott Siebert is
11	on the line. Do you know how many cases
12	currently are in the hopper, so to speak, for
13	dose reconstruction?
14	MR. SIEBERT: Yes, honestly, I
15	can't tell you.
16	CHAIRMAN GRIFFON: Okay.
17	MR. SIEBERT: That's not what I
18	track, sorry.
19	CHAIRMAN GRIFFON: That's all
20	right. That's all right.
21	DR. MAURO: You know, if it helps
22	any, I remember at the various presentations

1	of the number of adjudicated claims that are
2	often given at the Board meetings
3	MEMBER MUNN: Yes.
4	DR. MAURO: I remember you were
5	right around 25,000.
6	CHAIRMAN GRIFFON: Right.
7	MEMBER MUNN: Yes.
8	DR. MAURO: And, right now we are
9	at, well, I guess the 25,000 number, you
10	know, so trying to keep pace you know, in
11	the end the idea, I guess what I'm hearing
12	is, if there's 25,000 at this point in time,
13	that means eventually, I guess, you'd want to
14	audit a total of what?
15	MEMBER MUNN: A little over 500.
16	DR. MAURO: Yes.
17	CHAIRMAN GRIFFON: Yes.
18	DR. MAURO: A little over 500, and
19	right now we are at we are really at 250.
20	CHAIRMAN GRIFFON: Right.
21	DR. MAURO: So, I mean, I don't
22	know how do you whether you want to

1 CHAIRMAN GRIFFON: Yes, and the cases are going to continue to come in, but 2 they've definitely leveled off. 3 DR. MAURO: Not at the same pace, 4 that's right. 5 CHAIRMAN GRIFFON: Yes. 6 7 MR. KATZ: Mark, as far as I know there's 24,000 when you subtract out cases 8 that were pulled, and cases that went to the 9 10 FCC, and cases that have been returned, I 11 guess. Yes, so we are in the right ball 12 13 park. CHAIRMAN GRIFFON: So, I 14 Yes. mean, you know, that would be 500 -- 625 15 16 around for the 25,000 mark, and I would say, you know, the one thing -- I'm not sure that 17 we need to modify our selection process much. 18 19 I think the summary statistics give us some good information. I think we definitely want 20 more best-estimate cases, and those that sort 21

of fall in the 45-50 percent range, they may

1 not always be best estimates in that range. But, I think they usually do fall 2 into that, I think once -- now, Scott, you 3 may be able to help me out here, if you use 4 an over-estimating approach, and the POC 5 exceeds 45, do you then sharpen the pencil, 6 7 so to speak, as Jim Neton always says, and use a best estimate, or do you --8 MR. SIEBERT: Generally speaking, 9 10 it depends on the type of over-estimate that you use. If it's a gross over-estimate, such 11 as like OTIB-18, things like that, yes. 12 13 it's a relatively small over-estimate like using a DCF of 1, rather than the full 14 triangular distribution --15 CHAIRMAN GRIFFON: 16 Okay. 17 MR. SIEBERT: -- we may not do that. 18 19 CHAIRMAN GRIFFON: So, it's not that clean, but okay, instead of looking at 20 POC we may, and we've already started doing 21

that, actually, looking at -- Stu provides

that to us, but, you know, we look -- we sort of pre-select on POC, but then we asked Stu to break out the type of dose reconstruction full internal, full external, you know, et cetera.

So, you know, we've already really been doing that. But, I guess my point there is that Stu indicates in his graphic that based on the first 20,000 anyway, I guess his e-mail he sent was probably a little while ago, but based on the 20,000 number he said approximately 8 percent were best-estimate type, which would be 1,600, is that right, 1,600 cases?

So, if we were to shoot for our 40 percent goal, that, you know, I mean, 40 percent of our cases we want to be -- you know, so, in other words, there's still a population there, enough best-estimate cases that we can get 40 percent of our 600 cases to be best-estimate type cases, that's my point.

#### **NEAL R. GROSS**

1	MEMBER MUNN: Yes, I think we can.
2	CHAIRMAN GRIFFON: Yes.
3	MEMBER MUNN: I haven't seen any
4	evidence that there's any paucity of
5	material.
6	CHAIRMAN GRIFFON: Right. So, I
7	still think that's a reasonable goal.
8	MEMBER MUNN: Well, I haven't
9	seen, frankly, individual for myself, I
10	have not seen any real reason to consider
11	changing the parameters that we set out. We
12	went to considerable length to make sure that
13	we were trying to fit the
14	CHAIRMAN GRIFFON: I'm, actually,
15	trying to remember why this was raised. Was
16	it a question of overall scope? Maybe that's
17	the context that it came up in, but I feel
18	like we are fairly on target with it, and we
19	should
20	MEMBER MUNN: I think so, too. My
21	memory is the concern that we were having was
22	whether or not we were going to have an

1 adequate number of the assessment cases 2 available to us at any given time to do what we needed to do. Because there are --3 because of the other factors, the timing 4 things. 5 CHAIRMAN GRIFFON: Yes, and the 6 PER reviews and all those kind of things. 7 MEMBER MUNN: Right. 8 CHAIRMAN GRIFFON: Yes. 9 Yes.

MR. KATZ: Mark, the other item, this is Ted, was, in fact, I mean it was your concern, among -- I'm not sure about others on the Subcommittee, but it was certainly your concern or question as to whether the sample is big enough, or whether it needs to be increased, in other words, the number of dose reconstructions that get reviewed overall. So, that was a driver for having this discussion.

CHAIRMAN GRIFFON: Okay. I wanted more then -- I don't remember that, but, yes, I could have said that. I mean, I think -- I

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

know that I at one point raised a question as to whether we could -- whether SC&A could ramp up, but I think, really, sometimes the driver, as Wanda just sort of alluded to, is that, you know, we have to have, not only best-estimate cases, but best-estimate cases that are reviewable, you know.

MEMBER MUNN: Right.

CHAIRMAN GRIFFON: That have final adjudication. And, that, usually, is our limiting factor. So, I think the pace that we are at seems to make sense, and, John, I don't know if you agree with that, it seems like -- we've had a few glitches, but it seems like that pace for your folks is pretty good as well.

DR. MAURO: Yes, we are --

CHAIRMAN GRIFFON: You had the one delay where you had no cases, but then we got the 11th set going on. I think we --

DR. MAURO: Yes, you filled in the pipeline; we are working at just the pace we

#### **NEAL R. GROSS**

1 want to work at. If you wanted to kick it up, we have the capacity to do it, but I 2 think we're fine now. 3 The only thought I had, regarding 4 this whole matter, is we are seeing these 5 6 realistic cases, and we are seeing, I know I've seen the number -- it's over 45, to 45 7 and 50. 8 CHAIRMAN GRIFFON: 9 Yes. 10 DR. MAURO: And, I would be so bold as to say, it might be a good idea to 11 review all realistic cases that are between 12 45 and 50, all. 13 CHAIRMAN GRIFFON: That would be 14 15 bold. I mean, I'm not sure how many -- yes, 16 I think we have to reassess that. DR. MAURO: You know what it is; I 17 just wanted to stir the pot a little bit. 18 19 CHAIRMAN GRIFFON: Maybe we should -- you were afraid we were going to hang up 20 early. 21

#### **NEAL R. GROSS**

MEMBER MUNN:

22

That's a pretty big

spoon you are using to stir with, John.

DR. MAURO: I see numbers -- I've seen cases between 45 and 50. Now, I only look at AWEs. I have to say, I've seen a lot of potential reversals, once I started to look at those.

CHAIRMAN GRIFFON: Well, what I would say is, I think we need to -- maybe we should ask NIOSH to give us some numbers on that, too, how many best estimates fall -- because Scott just said, that they may not all be, you know, best estimates if they fall within 45 to 50, there may still be some over estimates in that. So, maybe we can fine tune that number, too, but if what Stu sent me is fairly accurate, you are talking about 1,600 cases in that 45 to 50 region, at least, and then that would be a significant increase from, you know, where we are going right now.

DR. MAURO: Is that right, there were that many realistic, between 45 and 50?

### **NEAL R. GROSS**

1	CHAIRMAN GRIFFON: Yes, that's
2	what it says.
3	DR. MAURO: Well, you may want to
4	crank it down the idea being, those that
5	are knocking on the door
6	CHAIRMAN GRIFFON: Yes.
7	DR. MAURO: now 45 is pretty
8	far away from 50, but I've seen, you know,
9	48, I just did a 49.6 case.
10	CHAIRMAN GRIFFON: Yes.
11	DR. MAURO: So, I mean, those are
12	important.
13	CHAIRMAN GRIFFON: No, no, no, I
14	agree. I agree, John. I agree with the
15	nature of your comment, I just
16	DR. MAURO: Yes, I know
17	CHAIRMAN GRIFFON: I'm not
18	ready to say, you know, as a policy decision
19	that the Subcommittee supports your view on
20	all best-estimate cases, I think we would
21	open a can of worms with that.
22	DR. MAURO: Within some POC range.

1 MEMBER MUNN: I wouldn't want to 2 do that. CHAIRMAN GRIFFON: Well, let's 3 look, you know what we can do is, ask NIOSH, 4 and I will ask this at the next Board 5 meeting, if we can get a further breakdown on 6 7 those best-estimate cases, and maybe Stu can probably run them all and just give us POCs 8 for all those that fall in that range, and we 9 10 can look and maybe there are -- you know, the ones for 48 to 50, maybe there's only, you 11 know, 75 of those, or 100 of those, or 12 13 whatever. MEMBER MUNN: We don't want to put 14 15 too fine an edge on this. CHAIRMAN GRIFFON: Yes. 16 MEMBER MUNN: Because it has an 17 enormously fine edge already. 18 19 CHAIRMAN GRIFFON: I think I like our number of 40 percent falling in that 20 range. I think that's still a pretty 21

22

aggressive sample.

MEMBER MUNN: Yes, it is an aggressive sample, and there are times, as has already been pointed out, when the pipeline makes it difficult for us to gather a large enough reading to really and truly make a decent selection.

CHAIRMAN GRIFFON: Yes.

MEMBER MUNN: And, we can't fool reality.

CHAIRMAN GRIFFON: I agree, and the other -- that's the other reason that I wouldn't, at this point anyway, recommend an increase in production, so to speak, for SC&A, because if we ask them to review more cases, you know, per year, the problem is the pipeline. I mean, you know, we are not going to have the cases, the types of cases that we want available. so, we won't get to that 40 percent of those between 45 and 50.

So, I think we should stay at the same rate, and, basically, stay with the same approach. I think we are okay.

#### **NEAL R. GROSS**

1 MEMBER MUNN: I don't see any real 2 reason to change it, as long as we have the level of -- the numbers of cases coming 3 through that will give us a decent sample to 4 choose from. 5 CHAIRMAN GRIFFON: Okay, then I'll 6 7 make that report back to the Board. I think we are okay. 8 MEMBER MUNN: I don't see any 9 10 pressing reason to change. CHAIRMAN GRIFFON: 11 No. MEMBER MUNN: I can think of 12 several academic reasons, but no real reality 13 check. 14 15 CHAIRMAN GRIFFON: Any --16 DR. MAURO: Mark, this is John, and the only thing, this came from an 17 outsider looking at the flow, I don't know 18 19 the rate at which new cases are coming in, but right now, you know, in terms of the 20 percent that was reviewed versus the percent 21

#### **NEAL R. GROSS**

that have been adjudicated, we are at 1

percent.

Assuming that we continue at 60 per year, that's what we are doing, 60 cases per year, that would -- you know, we would be holding at 1 percent if the number of adjudicated cases is increasing at 600 per year.

So, there's a way to get a handle on whether or not the throughput, the flow rate that we are currently doing, 60 per year, is, in fact, sufficient that when we are done, which I presume will be, you know, five years from now, will we have achieved the goal of 2-1/2 percent?

I think that's another question.

CHAIRMAN GRIFFON: Okay.

DR. MAURO: And, you may want to ask NIOSH to see, you know, if the flow is coming in much slower, then the 60 per year may very well -- because right now we are at 1 percent, and if we are holding at that pace, you know, we're going to start to get

#### **NEAL R. GROSS**

1	higher than 1 percent, in other words
2	CHAIRMAN GRIFFON: Right.
3	DR. MAURO: there's only 1,000
4	a year, instead of 6,000 a year come in,
5	then, you know, we will be catching up to the
6	2-1/2 percent eventually.
7	CHAIRMAN GRIFFON: Catching up,
8	right, yes.
9	MEMBER MUNN: And, it's my
10	observation that we probably are. I don't
11	remember those numbers, and I'm really sorry
12	I don't have the well, my suspicion is
13	that the flash drive I have here is probably
14	not the one with the most recent information
15	on it, but there's certainly been a leveling.
16	CHAIRMAN GRIFFON: Yes.
17	MEMBER MUNN: And, you know, we
18	are looking in terms of hundreds instead of
19	thousands.
20	DR. MAURO: I seem to recall
21	Larry's I don't know if it was Larry gave
22	the last presentation, was it 200 a month of

_	new cases coming in:
2	MEMBER MUNN: That sounds really
3	close to what my memory is.
4	DR. MAURO: Yes, which makes it
5	about 2,000 a year, which means we will catch
6	up a little bit.
7	CHAIRMAN GRIFFON: Yes.
8	MEMBER MUNN: Yes.
9	DR. MAURO: Correct, yes.
LO	CHAIRMAN GRIFFON: We'll close a
L1	little.
L2	DR. MAURO: Yes we will close the
L3	gap a bit.
L4	CHAIRMAN GRIFFON: And, I would
15	love to, you know, like you said, John, this
L6	definitely could be, I mean, a math problem
L7	here, but, you know, the sort of unknown
18	factor is, is this pipeline of 45 to 50 of
L9	the best-estimate cases available.
20	DR. MAURO: Yes, that's true.
21	CHAIRMAN GRIFFON: And, that
22	available part has been a bugaboo for us. I

mean, it's been a tricky thing, because of 1 2 the ongoing PER reviews. I know that for the 11th set, Stu, basically, sent us all the 3 best-estimate cases, and we were barely able 4 to get 25 cases for the review, you know? 5 DR. MAURO: Gotcha. 6 7 MEMBER MUNN: Yes. DR. MAURO: Yes. 8 CHAIRMAN GRIFFON: So, I think, 9 10 you know, I don't know that we can increase the flow. You know, I'd love to, but, you 11 know, slightly increase it, catch up a little 12 13 faster, but I just don't think we are going to have the cases there yet. 14 MEMBER MUNN: I don't see any 15 reason to expect that. 16 CHAIRMAN GRIFFON: Right, and I 17 don't want to review a lot of under-18 19 estimates, you know, I think we've got to target where we want to target, so we are 20 going to have to, you know, we are going to 21

have to pace it out like this, and maybe

revisit it, you know, every six months or so and see how we are doing.

MEMBER MUNN: We may even find ourselves in a situation where we have to use more than one set as the seed material to get the grouping that we want, to have an adequate number of best-estimate cases. It's just -- that's reality.

CHAIRMAN GRIFFON: Yes. Yes. So,

I think that's -- Brad or Mike, do you have

any comments? I think my report right now is

that we are going to stand with our current

policy and the current rate, and with the

explanations we've just offered here.

MEMBER CLAWSON: I have no problem with that, heading forward as you've been speaking earlier here. We may have to adjust later on and so forth, and I don't -- my issue is, Mark, is with the cases, and we discussed this in the last Dose Reconstruction Committee. So many times, I guess I'm looking at the Q&A a little bit,

#### **NEAL R. GROSS**

because many times when we've brought up issues they've said, well, you know, we never really did anything with this because this case was compensated.

My issue is, is if that's the case, what's happening to the ones below that, that are not -- you know, how are we taking this information that we are finding from these dose reconstruction reviews and so forth, and how is it playing back to the cases that aren't being compensated?

CHAIRMAN GRIFFON: Well, I think
that's -- yes, that's a fair question, Brad,
but I think we are -- we have accounted for
that in one respect, we've asked that part of
our criteria is to focus our selection on
newer cases, cases that have --

MEMBER CLAWSON: Right.

CHAIRMAN GRIFFON: -- been done more recently. So, if we don't see changes being made, then we are picking that up in our audit, you know.

#### **NEAL R. GROSS**

In other words, you know, NIOSH

indicated that they've modified a policy or

procedure, and then we review another case

from the same site that was done, you know, a

few years later, and it's still the same,

then, you know -
MEMBER CLAWSON: Right.

CHAIRMAN GRIFFON: -- so we have

to track that, I agree.

MEMBER CLAWSON: Right, it's just, you know, this has been something that has been coming up, and as we are talking about looking down, forward down the road, as John and also you and Wanda were saying, we may have to change our review a little bit to adjust for that, for things that we are seeing or whatever, because, you know, as the cases -- and I just want them to keep that in the back of our minds.

CHAIRMAN GRIFFON: Yes, reflect back on what we are seeing in our tracking.

The other thing I will mention is,

### **NEAL R. GROSS**

and that I'm going to mention in my report to
the Board next week, is this question of
adding in the dose reconstruction notes, and
I think once again I got it kind of from
NIOSH, but I do want to put it on the Board
record again, because I feel like that was
this is something committed to before, you
know, this idea. And, I think John might
have said it at one of the meetings, that,
you know, this is the idea of and getting
back to what Brad was just discussing the
idea of, you know, showing your work, you
know, if it's all there, and we have
something that years later from now can be
looked at in the archive, and you know
exactly how someone did a dose
reconstruction, that's sort of what we are
getting at here.

And so, that was one of our findings in this first 100 cases report, and I, you know, think we need to ask for that going forward. That will help look at that

## **NEAL R. GROSS**

1	thing that you are mentioning, Brad, which is
2	that, you know, were these changes made, and
3	are they adjusted, you know.
4	MEMBER CLAWSON: Right, and I
5	agree with you. I know, too, that this was
6	committed to a while back, too, but we still
7	have not seen that, and it makes it very
8	difficult to be able to go back, yes, this
9	OTIB, but this changed, and so forth like
LO	that.
11	So, if we know the process, I
12	think that it will beneficial.
13	CHAIRMAN GRIFFON: Right.
L4	MEMBER CLAWSON: To be able to do
15	that.
L6	CHAIRMAN GRIFFON: Okay. But, as
L7	far as the selection criteria, I think
18	Mike, do you have any comments on what we
L9	talked about for selection? I think we are
20	okay.
21	MEMBER GIBSON: No, not on the
22	selection criteria.

CHAIRMAN GRIFFON: Yes.

MEMBER GIBSON: I do agree with Brad, that, you know, I know NIOSH changes their policies and procedures, and all of that, but there is still that issue of the raw basic data that could be flawed from the plants that they used, even though they approved their process.

So, I agree, we need to keep an eye on that in the future.

CHAIRMAN GRIFFON: And, we are looking at that with different prongs, too.

We have our SEC process, certainly, addresses that on many of them, not all, but many of them.

And, John, alluded to these many set profile reviews that we've sort of picked up and said, well, wait a second, some of these sites we only look at one case for them, let's just look at the whole profile, instead of, you know, making a mini site profile review, instead of just an individual

#### **NEAL R. GROSS**

1	case, so that, I think that we've asked
2	SC&A to kind of go deeper than just did you
3	follow the procedure on those types of
4	things, because of that concern that you just
5	mentioned, Mike, that we want to know, you
6	know, the background basis for all the cases
7	done on this, since often times it's a
8	matrix, as John described.
9	Okay, so we'll leave that will
10	be my report on the selection criteria, and I
11	think I think that closes it out, unless
12	there's any other comments.
13	MEMBER MUNN: The big concern I
14	think was the letter.
15	CHAIRMAN GRIFFON: Yes, yes, and
16	thank you all for I'm sorry to send it out
17	so late, but I tried my best.
18	MEMBER MUNN: That's quite all
19	right, it happens to all of us. My apologies
20	for not having gotten to it last night, but
21	things

# **NEAL R. GROSS**

CHAIRMAN GRIFFON:

22

I know, and

1	you've got other things on your mind. I'm
2	sorry, Wanda.
3	MEMBER MUNN: Yes, that's quite
4	all right.
5	CHAIRMAN GRIFFON: Okay, Ted,
6	anything else for the record?
7	MR. KATZ: No, I think well done,
8	and I'm glad this will be closed out at the
9	next Board meeting then.
10	CHAIRMAN GRIFFON: Okay. I will
11	make these few modifications we discussed,
12	and send it around to all Board members
13	indicating that for the report that it's
14	coming as a Subcommittee proposal.
15	MEMBER MUNN: Great.
16	CHAIRMAN GRIFFON: I think we are
17	ready to adjourn.
18	MEMBER MUNN: Excellent.
19	CHAIRMAN GRIFFON: All right.
20	MR. KATZ: Thank you, everybody.
21	DR. MAURO: Bye. Take care.
22	MEMBER MUNN: Thank you for your

1	participation. Bye-bye.
2	CHAIRMAN GRIFFON: Bye.
3	(Whereupon, the above-entitled matter
4	was went off the record at 11:57 a.m.)
5	
6	
7	
8	
9	
LO	
L1	
L2	
L3	
L4	
L5	
L6	
L7	
L8	
19	
20	
21	
22	

# **NEAL R. GROSS**